Journals / Retina-Vitreus / 2016 / Cilt: 24 - Sayı: 1

Combined Vitrectomy with Intravitreal Triamcinolone Followed By Laser Photocoagulation in Refractory Diabetic Macular Edema

Dirençli Diyabetik Maküla Ödeminde Kombine Vitrektomi-İntravitreal Triamsinolon Sonrası Lazer Fotokoagülasyon

Pages
13–18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed for more information.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To investigate the efficacy and safety of vitrectomy with triamcinolone acetonide (IVTA) injection followed by laser photocoagulation (LP) for diabetic macular edema (DME) refractory to anti-'vascular endothelial growth factor' (VEGF).Materials and Methods: Eleven eyes of 11 patients with DME refractory to anti-VEGF treatment.
📊
Key Findings & Data:Patients underwent combined vitrectomy, internal limiting membrane (ILM) peeling with IVTA (4 mg) and 1 month later followed by argon LP.
💡
Conclusion & Impact:Further studies are needed for more information.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To investigate the efficacy and safety of vitrectomy with triamcinolone acetonide (IVTA) injection followed by laser photocoagulation (LP) for diabetic macular edema (DME) refractory to anti-'vascular endothelial growth factor' (VEGF).Materials and Methods: Eleven eyes of 11 patients with DME refractory to anti-VEGF treatment. Patients underwent combined vitrectomy, internal limiting membrane (ILM) peeling with IVTA (4 mg) and 1 month later followed by argon LP. Corrected visual acuity (CVA), intraocular pressure (IOP) and central macular thickness (CMT) were measured and compared at baseline and one, three, and six months (respectively) after vitrectomy.Results: Eleven eyes of 11 patients [5(46.15%) male, 6(53.85%) female] with a mean age of 62.0±4.85 years (59-72 years) were included in this study. The mean IOP were 17.73±1.10 mmHg; 19.09±1.87 mmHg (p=0.015) and 19.73±1.68 mm Hg (p=0.006) respectively. The mean CMTs were 506.64±73.81 microns, 437.64±63.64 microns, 389.92±63.75 microns and 358.09±54.35 microns respectively (p=0.003). The mean CVAs (Log MAR) were 2.21±0.52 LogMAR, 1.77±0.63 LogMAR, 1.34±0.68 LogMAR, and 1.34±0.81, respectively. The values of both BCVA and CMT at one, three, and six months were significantly improved from baseline (p=0.003).Conclusions: In our study, combined vitrectomy with IVTA and followed by LP is found to be safe and effective for DME refractory to anti-VEGF therapy. Further studies are needed for more information.

Özet

Amaç: İntravitreal (İV) anti 'Vascular endothelial growth factor' (VEGF) tedavisine dirençli diyabetik makula ödemi (DMÖ)'nde, İV triamsinolon asetonid (İVTA) ile kombine vitrektomi ameliyatı ve sonrası laser fotokoagülasyon (LFK) tedavisinin etkinlik ve güvenilirliğini araştırmak.Gereç ve Yöntem: Çalışmaya İV anti-VEGF tedaviye dirençli DMÖ'lü 11 hastanın 11 gözü dahil edildi. Hastalara İVTA ile kombine vitrektomi-iç limitan membran soyulması ameliyatı ve bir ay sonra LFK tedavisi yapıldı. Hastaların düzeltilmiş görme keskinlikleri (DGK), göz içi basıncı (GİB), santral makula kalınlığı (SMK) ölçümleri vitrektomi ameliyatı öncesi ve ameliyattan 1 ay, 3 ay ve 6 ay sonra saptandı ve karşılaştırıldı.Bulgular: Çalışmaya 5 (%46.15)'i erkek, 6 (%53.85)'sı kadın toplam 11 hastanın 11 gözü dahil edildi. Hastaların ortalama yaşı 62.0±4.85 yıl (59-72 yıl) idi. Hastaların GİB ölçümleri vitrektomi ameliyatı öncesi 17.73±1.10 mm Hg iken ameliyattan 1 ay sonra 19.09±1.87 mm Hg (p=0.015), 3 ay sonra ise 19.73±1.68 mm Hg (p=0.006) anlamlı olarak yükseldiği görüldü. Hastaların SMK ölçümü vitrektomi ameliyatı öncesi 506.64±73.81 mikron iken anlamlı olarak azalarak ameliyattan 1 ay sonra 437.64 ±63.64 mikron, 3 ay sonra 389.92±63.75 mikron, 6 ay sonra 358.09±54.35 mikron olarak saptandı (p=0.003). Hastaların DGK ölçümü vitrektomi ameliyatı öncesi 2.21±0.52 Log MAR iken anlamlı olarak azalarak ameliyattan 1 ay sonra 1.77±0.63 Log MAR, 3 ay sonra 1.34±0.68 LogMAR, 6 ay sonra 1.34±0.81 LogMAR olarak saptandı (p=0.003). Tartışma: Çalışmamızda İV anti-VEGF tedavisine dirençli DMÖ'de, İVTA ile kombine vitrektomi ameliyatı ve sonrası LFK tedavisi etkin ve güvenilir olarak bulundu. Daha kesin sonuçlar için ileri çalışmalara ihtiyaç vardır.

🔖

Cite This Article

BARDAK, H., BARDAK, Y., EKİM, M. M. (2016). Combined Vitrectomy with Intravitreal Triamcinolone Followed By Laser Photocoagulation in Refractory Diabetic Macular Edema. Retina-Vitreus, Cilt: 24 - Sayı: 1, 13–18. https://ajindex.com/articles/308005

References (12)

  1. Early treatment diabetic retinopathy study research group. Photo coagulation for diabetic macular edema: Early treat- ment diabetic retinopathy study report number 1. Arch Oph- thalmol 1985; 103:1796-806. Diabetic retinopathy clinical research network, Chew E, Strauber S, et al. Randomized trial of peribulbar triamcino- lone acetonide with and without focal photo coagulation for mild diabetic macular edema: A pilot study. Ophthalmology 2007;114:1190-6.
  2. Entezari M, Ahmadieh H, Dehghan MH, et al. Posterior sub- tenon triamcinolone for refractory diabetic macular edema: A randomized clinical trial. Eur J Ophthalmol 2005;15:746-50.
  3. Jonas JB, Sofker A. Intraocular injection of crystalline corıtisone as adjunctive treatment of diabetic macular ede- ma. Am J Ophthalmol 2001;132:425-7.
  4. Martidis A, Duker JS, Greenberg PB, et al. Intravitre- al triamcinolone for refractory diabetic macular edema. Ophıthalmology 2002;109:920-7.
  5. Massin P, Audren F, Haouchine B, et al. Intravitreal triam- cinolone acetonide for diabetic diffuse macular edema: Prelim- inary results of a prospective controlled trial. Ophthalmology 2004; 111:218-24.
  6. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multi cen- ter phase II study. Diabetes Care 2010;33:2399-405.
  7. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: Report 2. Ophthalmology 2010;117:1078-86.
  8. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcino- lone versus macular photo coagulation in diabetic macular edema. Ophthalmology 2009;116:1142-50.
  9. Biarnes M, MonesJ, Villali JR, Arias L. As-needed treat- ment with ranibizumıab 0.5 mg in patients with neovascu- lar age-related macular degeneration. Eur J Ophthalmol, 2011;21: 282-89.
  10. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina 2008;28:420-6.
  11. Kumagai K, Furukawa M, Ogino N, et al. Long-term follow- up of vitrectomy for diffuse nontractional diabetic macular edema. Retina 2009;29:464-72.
  12. Kim J H, KangS W, Ha H S, Kim J R. Vitrectomy combined with intravitreal triamcinolone acetonide injection and macu- lar laser photo coagulation for nontractional diabetic macular ed